Med24
Klinisk medisin 19. 10. 2026 • 2 min read • MedPage Today

Ny Behandling Godkjent for Anal Cancer – Dostarlimab

FDA har godkjent dostarlimab for bruk hos utvalgte pasienter med opererbart anal cancer. Denne behandlingen, basert på AZUR-1 studien, gir et nytt håp for pasienter med spesifikke genetiske egenskaper i kreftvevet.

'Groundbreaking Option' Approved for Rectal Cancer

The Food and Drug Administration granted accelerated approval to dostarlimab for use in select patients with operable rectal cancer. This approval applies to stage II/III patients identified with mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) rectal cancer, representing approximately 3% of locally advanced cases. Patients achieving a complete response may potentially avoid standard treatment, which typically includes chemotherapy, radiation, and surgery. Support for this approval stems from the AZUR-1 trial.

The AZUR-1 trial demonstrated that the majority of patients with dMMR/MSI-H rectal cancers and other solid tumors treated with dostarlimab achieved a complete response and were able to avoid surgery. Principal investigator Andrea Cercek noted the potential for neoadjuvant PD-1 inhibition to eradicate the need for traditional therapies in a subset of patients. An exploratory analysis of AZUR-1 showed that 76% of evaluable patients had no evidence of cancer a year or more after treatment, with no recurrences reported after more than 2 years of follow-up.

Sponsored content

Adverse events observed in the AZUR-1 trial included fatigue, rash, diarrhea, and pruritus. Grade 3 adverse events included diabetes, lung infection, hypothyroidism, encephalitis, and neutropenia. The labeling notes the potential for immune-mediated adverse events. Continued approval may be contingent upon verification of clinical benefit in a confirmatory trial. Dostarlimab has multiple approved indications in endometrial cancer and is approved for previously treated dMMR recurrent or advanced solid tumors.

Original Scientific Source
MedPage Today
View Original Source
Medisinsk ansvarsfraskrivelse Alle beregninger, råd og tolkninger på dette nettstedet er kun ment til informasjons- og opplysningsformål. De erstatter ikke profesjonell medisinsk undersøkelse, diagnose eller behandling. Rådfør deg alltid med lege ved helsespørsmål.

Recommended Medical News

All news →
Pasienters Opplevelse av 'Hjernetåke' ved Søvnforstyrrelser
Klinisk medisin

Pasienters Opplevelse av 'Hjernetåke' ved Søvnforstyrrelser

En analyse av sosiale medier fra pasienter med søvnforstyrrelser, spesielt narcolepsi og idiopatisk hypersomni, avslører at 'hjernetåke' primært beskrives som hukommelsestap, vanskeligheter med konsentrasjon og glemsomhet. Studiens funn har viktige implikasjoner for utvikling av pasientrapporterte utfallsmål.

8. 11. 2026 Read article →
Advertisement